| Code | CSB-RA011087MB9HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to VRDN-003, designed for research targeting the insulin-like growth factor 1 receptor (IGF1R). IGF1R is a receptor tyrosine kinase that plays a critical role in cellular growth, proliferation, differentiation, and survival through activation of downstream PI3K/AKT and MAPK signaling pathways. This receptor mediates the biological effects of IGF1 and IGF2, contributing to normal development and tissue homeostasis. Aberrant IGF1R signaling has been implicated in multiple cancers, including breast, lung, colorectal, and prostate cancers, where it promotes tumor growth, metastasis, and resistance to therapy. Additionally, dysregulation of the IGF1R pathway is associated with metabolic disorders and aging-related processes.
VRDN-003 represents a therapeutic antibody developed to inhibit IGF1R signaling in oncology research. This biosimilar provides researchers with a valuable tool for investigating IGF1R-mediated mechanisms in cancer biology, studying receptor-ligand interactions, evaluating therapeutic resistance pathways, and exploring combination treatment strategies. It enables detailed examination of IGF1R's role in disease progression and therapeutic intervention.
There are currently no reviews for this product.